Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.
Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S, Duong MN, Reslan L, Gerdes CA, Friess T, Baer U, Burtscher H, Weidner M, Dumontet C, Umana P, Niederfellner G, Bacac M, Klein C. Herter S, et al. Among authors: bacac m. Mol Cancer Ther. 2013 Oct;12(10):2031-42. doi: 10.1158/1535-7163.MCT-12-1182. Epub 2013 Jul 19. Mol Cancer Ther. 2013. PMID: 23873847
Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors.
Thommen DS, Schreiner J, Müller P, Herzig P, Roller A, Belousov A, Umana P, Pisa P, Klein C, Bacac M, Fischer OS, Moersig W, Savic Prince S, Levitsky V, Karanikas V, Lardinois D, Zippelius A. Thommen DS, et al. Among authors: bacac m. Cancer Immunol Res. 2015 Dec;3(12):1344-55. doi: 10.1158/2326-6066.CIR-15-0097. Epub 2015 Aug 7. Cancer Immunol Res. 2015. PMID: 26253731
Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy.
Gonzalez-Nicolini V, Herter S, Lang S, Waldhauer I, Bacac M, Roemmele M, Bommer E, Freytag O, van Puijenbroek E, Umaña P, Gerdes CA. Gonzalez-Nicolini V, et al. Among authors: bacac m. Clin Cancer Res. 2016 May 15;22(10):2453-61. doi: 10.1158/1078-0432.CCR-14-2579. Epub 2015 Nov 18. Clin Cancer Res. 2016. PMID: 26581243
A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents.
Herter S, Morra L, Schlenker R, Sulcova J, Fahrni L, Waldhauer I, Lehmann S, Reisländer T, Agarkova I, Kelm JM, Klein C, Umana P, Bacac M. Herter S, et al. Among authors: bacac m. Cancer Immunol Immunother. 2017 Jan;66(1):129-140. doi: 10.1007/s00262-016-1927-1. Epub 2016 Nov 17. Cancer Immunol Immunother. 2017. PMID: 27858101 Free PMC article.
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P. Klein C, et al. Among authors: bacac m. Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017. Oncoimmunology. 2017. PMID: 28405498 Free PMC article.
75 results